Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS)

Journal of Dermatological Science

Volumn 13, Issue 1, 1996, Pages 18-24

  Maeda, Manabu ^a   Kachi, Hisayo ^a   Kitajima, Yasuo ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Blood coagulation; Circadian variation; Fibrinolysis; PSS

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BETA THROMBOGLOBULIN; FIBRINOPEPTIDE A; PREDNISOLONE; THROMBIN; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

EID: 0030271299     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/0923-1811(95)00484-X     Document Type: Article

References (35)

1. [1] Barnett AJ: Scleroderma (progressive systemic sclerosis). Charles C. Thomas Publisher, Springfield, USA, 1974, pp. 71-93.
2. [2] Maeda M, Mori S: Occupational or extrinsic stimulation factors and initial signs of progressive systemic sclerosis. Int J Dermatol 31: 257-259, 1992.
3. [3] Maeda M, Matubara K, Hirano H, Watabe H, Ichiki Y, Mori S: Pitting scars in progressive systemic sclerosis. Dermatology 187: 104-108, 1993.
4. [4] Falanga V, Krustal JB, Franks JJ: Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma). J Am Acad Dermatol 25: 771-775, 1991.
5. [5] Kahaleh MB, Osborn I, LeRoy EC: Elevated levels of circulating platelet aggregates and β-thromboglobulin in scleroderma. Ann Int Med 96: 610-613, 1982.
6. [6] Maeda M, Shikano Y, Ichiki Y, Mori S: Plasma platelet-derived factors in patients with PSS Alterations of plasma β-thromboglobulin and platelet factor 4 levels after vibration stress on bilateral hands. Jpn J Dermatol 98: 1205-1209, 1988.
7. [7] Petralito A, Mangiafico RA, Oibiino S, Cuffari MA, Miano MF. Fiore CE: Daily modifications of plasma fibrinogen, platelet aggregation. Howell's time, PTT, TT and antithrombin III in normal subjects and in patients with vascular disease. Chronobiologia 9: 195-201, 1982.
8. [8] Grimaudo V, Hauert J, Bachmann F, Kruithof EKO: Diurnal variation of the fibrinolystic system. Thromb Heamostas 59: 495-499, 1988.
9. [9] Decousus HA, Croze M, Levi F, Janbert JO, Perpoint BM. DeBonadona JP, Reinberg A, Queneau PM: Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 290: 341-344, 1985.
10. [10] Krulder JW, Van den Besselaar AM, Van der Meer FJ, Meinders AE, Briet E: Diurnal changes in heparin effect during continuous constant-rate infusion. A study in nine patients with venous thrombosis. J Int Med 235: 411-417, 1994.
11. [11] Pechan J, Mikulecky M, Okrucka A: Circadian rhythm of plasma beta-thromboglobulin in healthy human subjects. Blood Coag Fibrinol 3: 105-107, 1992.
12. [12] Takada A, Takada Y, Urano T, Sakakibara K, Rydzewski A: Circadian variations in blood coagulation parameters, α-antitrypsin and platelet aggregation and retention in clinically healthy subjects. Thromb Res 57: 13-20, 1990.
13. [13] Yamakage A, Ishikawa H: Generalized morphea-like scleroderma occuring in people exposed to organic solvents. Dermatologica 165: 186-193, 1982.
14. [14] Mori S: Preliminary diagnostic criteria in Japan. Scleroderma International Symposium current topics in Scleroderma. Organized by Scleroderma Reseach Committee (Chairman: S. Mori) Ministry of Health and Welfare in Japan, Seino Printing Co. Ltd., Oifu, Japan, 1992, pp. 17-26.
15. [15] Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J: Circadian variations in blood coagulation parameters, α-antitrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Int 7: 203-216, 1990.
16. [16] Decousus H, Boissier C, Pejpoint B, Page Y, Mismetti P, Laporte S, Tardy B, Quebeau P: Circadian dynamics of coagulation and chronopathology of cardiovascular and cerebrovascular events. Further therapeutic implications for the treatment of these disorders? Ann New York Acad Sci 618: 159-165, 1991.
17. [17] Tofler OH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Oleason RE, Williams OH, Muller JE: Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden death. New Engl J Med 316: 1514-1518, 1987.
18. [18] Muller JE, Ludmer PL, Willich SN, Tofler OH, Aylmer O, Klangos I, Stone PH: Circadian variation in the frequency of sudden cardiac death. Circulation 75: 131-138, 1987.
19. [19] Morrison JF, Pearson SB, Deaan HG, Craig IR, Bramley PN: Platelet activation in noctural asthma. Thorax 46: 197-200, 1991.
20. [20] Oresele P, Dottorini M, Selli ML, Iannacci L, Canino S, Todisco T, Romano S, Crook P, Page CP, Nenci GG: Altered platelet function associated with the bronchial hyper-responsiveness accompanying nocturnal asthma. J Allergy Clin Immunol 91: 894-902, 1993.
21. [21] Keegan AC, Holland CD, Jayson MIV: Loss of diurnal variation in fibrinolytic activities in systemic sclerosis (abstruct). Br J Rheumatol 24: 21, 1985.
22. [22] Lee P, Norman CS, Sukenik S, Alderdice CA: The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma). J Rheumatol 12: 514-517, 1985.
23. [23] Greaves M, Malia RG, MilfordWard A, Moult J, Holt CM, Lindsey N, Hughes P, Goodfiold M, Rowell NR: Elevated von Willebrand factor antigen in systemic sclerosis: Relationship to visceral disease. Br J Rheumatol 27: 281-285, 1988.
24. [24] Smith EA, LeRoy EC: A possible role for transforming growth factor in systemic sclerosis. J Invest Dermatol 95: 125s-127s, 1990.
25. [25] Maeda, Kachi H, Mori S: Plasma levels of molecular markers of blood coagulation and fibrinolysis in progressive systemic sclerosis (PSS). J Dermatol Sci, 1995 (in print).
26. [26] Lima J, Fonollosa V, Fernandez-Cortiji J, Ordi J, Cuenca R, Khamashta MA, Vilardell M, Simeon CP, Pico M: Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 18: 1833-1836, 1992.
27. [27] Goodfield MJD, Orchard MA, Rowell NR: Increased platelet sensitivity to collagen-induced aggregation in whole blood in patients with systemic sclerosis. Clin Exp Rheumatol 6: 285-288, 1988.
28. [28] Pandolfi A, Florita M, Altomare O, Pigatto P, Donati MB, Poggi A: Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. PSEBM 191: 1-4, 1989.
29. [29] Klareskog L, Oustafsson R, Scheynius A, Hallgren R: Increased expression of platelet-derived growth factor sclerosis group B receptors in the skin of patients with systemic sclerosis. Arth Rheum 33: 1534-1541, 1990.
30. [30] Falanga V, Hebda PA, Eaglstein WH: Effect of platelet homogenate on in vitro glycosaminoglycan production by dermal fibroblasts from systemic sclerosis patients and normal controls. Br J Dermatol 113: 237-243, 1985.
31. [31] Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M: Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175: 1227-1234.
32. [32] Smith EA, LeRoy EC. A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990; 95: 125s-127s.
33. [33] Rocha E: Clotting activation and impairment of fibrinolysis in malignacy. Thromb Res 54: 699-707, 1989.
34. [34] Takehara H: Thrombin and plasmin generation in patients with liver disease. Am J Hematol 32: 30-35, 1989.
35. [35] Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, Jannone P, Beneforti E, Cinotti S, Morfin M, Caignoni M: Cutanous and plasma fibrinolytic activity in systemic scierosis. Evidence of normal plasminogen activation. Int J Dermatol 29: 644-648, 1990.